Junshi-Coherus FDA Review of the Biologics License Application Delayed

 - FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA -

- Junshi Biosciences and Coherus are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for patients with NPC in the U.S. as quickly as possible -

https://finance.yahoo.com/news/junshi-biosciences-coherus-share-fda-131600966.html